Research ExplorerPublications[Remifentanil-based intraoperative anaesthesia and postopera...

[Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?]

Standard

[Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?]. / Zöllner, Christian; Schäfer, M.

In: ANAESTHESIST, Vol. 56, No. 10, 10, 2007, p. 1038-1046.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Zöllner, C & Schäfer, M 2007, '[Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?]', ANAESTHESIST, vol. 56, no. 10, 10, pp. 1038-1046. <http://www.ncbi.nlm.nih.gov/pubmed/17762929?dopt=Citation>

APA

Zöllner, C., & Schäfer, M. (2007). [Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?]. ANAESTHESIST, 56(10), 1038-1046. [10]. http://www.ncbi.nlm.nih.gov/pubmed/17762929?dopt=Citation

Vancouver

Zöllner C, Schäfer M. [Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?]. ANAESTHESIST. 2007;56(10):1038-1046. 10.

Bibtex

@article{159ca01f5abd49098f54a62f53938409,
title = "[Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?]",
abstract = "Remifentanil is a synthetic opioid derivate with an agonist activity at mu-opioid receptors. The pharmacokinetic profile differs from other synthetic opioids. Remifentanil is rapidly metabolised by unspecific blood and tissue esterases and the metabolites have almost no intrinsic activity. According to its unique pharmacokinetic profile, remifentanil-based anaesthesia might be associated with a high level of postoperative pain, therefore, an appropriate postoperative pain management is an import aspect. In addition, remifentanil withdrawal induces a compensatory up-regulation of secondary messenger pathways, inducing hyperalgesia. This review provides a comprehensive summary of basic and clinical research concerning the intraoperative use of remifentanil and postoperative pain therapy. The relative contribution of rapid degradation and withdrawal-induced hyperalgesia to postoperative pain will be discussed. In addition, this review attempts to identify potential clinical implications and treatment strategies.",
author = "Christian Z{\"o}llner and M Sch{\"a}fer",
year = "2007",
language = "Deutsch",
volume = "56",
pages = "1038--1046",
journal = "ANAESTHESIST",
issn = "0003-2417",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - [Remifentanil-based intraoperative anaesthesia and postoperative pain therapy. Is there an optimal treatment strategy?]

AU - Zöllner, Christian

AU - Schäfer, M

PY - 2007

Y1 - 2007

N2 - Remifentanil is a synthetic opioid derivate with an agonist activity at mu-opioid receptors. The pharmacokinetic profile differs from other synthetic opioids. Remifentanil is rapidly metabolised by unspecific blood and tissue esterases and the metabolites have almost no intrinsic activity. According to its unique pharmacokinetic profile, remifentanil-based anaesthesia might be associated with a high level of postoperative pain, therefore, an appropriate postoperative pain management is an import aspect. In addition, remifentanil withdrawal induces a compensatory up-regulation of secondary messenger pathways, inducing hyperalgesia. This review provides a comprehensive summary of basic and clinical research concerning the intraoperative use of remifentanil and postoperative pain therapy. The relative contribution of rapid degradation and withdrawal-induced hyperalgesia to postoperative pain will be discussed. In addition, this review attempts to identify potential clinical implications and treatment strategies.

AB - Remifentanil is a synthetic opioid derivate with an agonist activity at mu-opioid receptors. The pharmacokinetic profile differs from other synthetic opioids. Remifentanil is rapidly metabolised by unspecific blood and tissue esterases and the metabolites have almost no intrinsic activity. According to its unique pharmacokinetic profile, remifentanil-based anaesthesia might be associated with a high level of postoperative pain, therefore, an appropriate postoperative pain management is an import aspect. In addition, remifentanil withdrawal induces a compensatory up-regulation of secondary messenger pathways, inducing hyperalgesia. This review provides a comprehensive summary of basic and clinical research concerning the intraoperative use of remifentanil and postoperative pain therapy. The relative contribution of rapid degradation and withdrawal-induced hyperalgesia to postoperative pain will be discussed. In addition, this review attempts to identify potential clinical implications and treatment strategies.

M3 - SCORING: Zeitschriftenaufsatz

VL - 56

SP - 1038

EP - 1046

JO - ANAESTHESIST

JF - ANAESTHESIST

SN - 0003-2417

IS - 10

M1 - 10

ER -